Choose a folder
New trends of treatment reality versus guidelines from 32 countries presented at EASD 2017
Dr Marilia Gomes of the DISCOVER Scientific Committee presented an exciting new analysis of treatment reality versus guidelines from the DISCOVER study at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), 11–15 September in Lisbon, Portugal.
This analysis of data from 14 178 DISCOVER patients showed that, overall, glycated haemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) levels were documented in 77.5%, 51.2% and 94.9% of patients, respectively. Of patients with available data, only 6.7% met the guideline-recommended targets for all three variables. Additionally, while elevated HbA1c levels are expected in patients initiating second-line therapy, less than one-third of individuals with available data achieved targets for both LDL-C and SBP. These findings demonstrate a clear need for global interventions aimed at improving attainment of HbA1c, LDL-C and SBP targets.
A second poster was also presented at EASD 2017 describing metformin discontinuation in patients with type 2 diabetes initiating second-line treatment. The DISCOVER Scientific Committee also presented encore presentations on glycaemic control, vascular complications and treatment patterns. More information about these presentations can be found on the DISCOVER website here.
Thank you to all the DISCOVER investigators for their efforts to collect the data that make this study possible. For further updates, please keep visiting the DISCOVER website.
Approval ID: Z4-7481 Date of preparation: 12 October 2017 Date of expiry: 12 October 2018